Albert David Ltd
ALBERTDAVD
Company Profile
Business description
Albert David Ltd is engaged in the manufacturing and trading of pharmaceutical products. The company offers products such as pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. Its formulation product covers parenteral, oral, enteral, topical agents, and vision care solutions. The company exports its product to regions like Latin America, Southeast Asia, and a few African countries. The Company is only engaged in the manufacturing of pharmaceutical products, ipso facto, one reportable segment.
Contact
8, Netaji Subhas Road
D-Block, 3rd Floor, Gillander House
KolkataWB700001
INDT: +91 3322628436
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,805
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,267.90 | 22.11 | 0.27% |
| DAX 40 | 23,869.26 | 62.27 | 0.26% |
| Dow JONES (US) | 48,042.66 | 143.14 | -0.30% |
| FTSE 100 | 10,603.66 | 0.18 | 0.00% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,981.87 | 159.45 | 0.70% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,181.44 | 92.37 | -0.70% |
| S&P 500 | 6,837.65 | 12.99 | 0.19% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |